Utilizing red blood cell distribution width (RDW) as a reliable biomarker to predict treatment effects after chimeric antigen receptor T cell therapy
Clinical and Experimental Medicine · 2024
DOI: 10.1007/s10238-024-01373-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2024. Verfasst von Naokazu Nakamura und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Kyoto University Hospital, Kyoto, Japan. Hauptthemen laut MEDLINE: Erythrocyte Indices, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Chimeric antigen receptor T cell (CAR-T) therapy is an effective treatment for B cell malignancies. A certain fraction of patients, however, experience post-CAR-T relapse, and due to the difficulty of precise relapse prediction, biomarkers that can predict the strength and duration of CAR-T efficacy are needed before CAR-T infusion. Therefore, we performed a single-center cohort study including 91 diffuse large B cell lymphoma (DLBCL) patients treated with CAR-T in order to identify such a new prognostic biomarker. After confirming that each of the already reported prognostic parameters (disease status at leukapheresis, primary refractoriness, number of treatment lines, CD3 + cell counts at leukapheresis) has only limited predictive performance, we established a new composite parameter by integrating these four variables, and found that it predicts progression-free survival (PFS) after CAR-T infusion with statistical significance. Moreover, after comprehensive correlation analyses of this new composite parameter with all individual laboratory variables, we determined that the standard deviation of red blood cell distribution width (RDW-SD) at leukapheresis shows significant correlation with the composite parameter and may be a prognostic biomarker ( R 2 = 0.76, p = 0.02). Validation analysis indicated that a higher RDW-SD is significantly associated with poorer PFS after CAR-T cell therapy (HR, 3.46, P = 0.03). Thus, this study suggests that a single parameter, RDW-SD at leukapheresis, is a novel, useful biomarker that can be obtained early to predict therapeutic effects of CAR-T cell therapy. Post-CAR-T maintenance or re-induction therapies should be adopted for higher risk patients, who may relapse after CAR-T therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Kyoto University Hospital, Kyoto, Japan.
- Department of Clinical Laboratory Medicine, Kyoto University Hospital, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
- Department of Hematology, Kyoto University Hospital, Kyoto, Japan. ysykrai@kuhp.kyoto-u.ac.jp.
- Department of Clinical Laboratory Medicine, Kyoto University Hospital, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. ysykrai@kuhp.kyoto-u.ac.jp.
- Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Zitieren
APA
Nakamura, N., Jo, T., Arai, Y., Kitawaki, T., Nishikori, M., Mizumoto, C., Kanda, J., Yamashita, K., Nagao, M., & Takaori-Kondo, A. (2024). Utilizing red blood cell distribution width (RDW) as a reliable biomarker to predict treatment effects after chimeric antigen receptor T cell therapy. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01373-5
Vancouver
Nakamura N, Jo T, Arai Y, Kitawaki T, Nishikori M, Mizumoto C, et al. Utilizing red blood cell distribution width (RDW) as a reliable biomarker to predict treatment effects after chimeric antigen receptor T cell therapy. Clinical and Experimental Medicine. 2024. doi:10.1007/s10238-024-01373-5
BibTeX
@article{Nakamura2024,
author = {Nakamura, Naokazu and Jo, Tomoyasu and Arai, Yasuyuki and Kitawaki, Toshio and Nishikori, Momoko and Mizumoto, Chisaki and Kanda, Junya and Yamashita, Kouhei and Nagao, Miki and Takaori-Kondo, Akifumi},
title = {Utilizing red blood cell distribution width (RDW) as a reliable biomarker to predict treatment effects after chimeric antigen receptor T cell therapy},
journal = {Clinical and Experimental Medicine},
year = {2024},
doi = {10.1007/s10238-024-01373-5}
}
EUVIMED